Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Mirzotamab clezutoclax + Temozolomide |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Mirzotamab clezutoclax | ABBV-155|ABBV 155|ABBV155 | BCL-XL inhibitor 14 CD276 Antibody 21 | Mirzotamab clezutoclax (ABBV-155) is an antibody-drug conjugate (ADC) consisting of a BCL-XL inhibitor linked to a monoclonal antibody targeted against CD276 (B7H3), which may have antitumor activity (J Clin Oncol 39, no. 15_suppl (May 20, 2021) 3015). | |
| Temozolomide | Temodar | Methazolastone|TMZ | Chemotherapy - Alkylating 18 | Temodar (temozolomide) is a dacarbazine analog and cytotoxic alkylating agent (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06934889 | Phase I | ABBV-637 + ERAS-801 ABBV-637 + Temozolomide ERAS-801 + Mirzotamab clezutoclax Mirzotamab clezutoclax + Temozolomide | Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | Recruiting | USA | 0 |